Latest Observability News

Kincora Copper has kicked off a capital-efficient, sole-funded drilling campaign at its 100%-owned Condobolin gold-silver-base metals project in NSW’s Cobar Basin, targeting extensions to the high-grade Meritilga discovery and testing new geochemical and geophysical anomalies.

Regener8 Resources has secured a binding agreement to acquire the Srebrenica North Project in Bosnia and Herzegovina, complemented by a successful $800,000 placement and a $2.87 million entitlement offer to fund exploration and due diligence.

QMines Limited’s latest drilling at Mount Mackenzie confirms a broad, structurally controlled high-grade gold system with multiple mineralised zones open at depth and along strike.

Yandal Resources has confirmed a 100m southeast extension of high-grade gold mineralisation at its Arrakis discovery, with significant new RC drill results supporting underground exploration potential.

White Cliff Minerals has intersected visual copper sulphides in all five initial drillholes at its Danvers copper deposit in Nunavut, including a significant step-out over 5.2km, validating the Teshierpi Fault Zone as a major copper-bearing structure.

Torque Metals has appointed the former Spartan Resources leadership team to drive growth at its Paris Gold Project, reporting strong high-grade drilling results that extend mineralisation well beyond current resource boundaries. An updated Mineral Resource Estimate is expected in Q2 2026, supported by a robust cash position.

BPM Minerals has completed key surveys at its Bonnie & Clyde Prospect within the Forelands Gold Project, setting the stage for maiden drilling in Q3 2026. The project’s geological complexity and strong geochemical anomalies underline its potential for a major gold discovery.

Sabre Resources (ASX:SBR) has secured 80% stakes in two companies holding nearly 4,000km² of highly prospective gold and copper-gold projects in the Northern Territory, including drill-ready targets analogous to the Tennant Creek Mineral Field. A heavily supported $2 million placement will fund aggressive exploration including imminent drilling.

Chimeric Therapeutics' CHM CORE-NK cell therapy achieved a 60% complete response rate in high-risk frontline AML patients, significantly exceeding typical outcomes and maintaining a strong safety profile.

Solstice Minerals has pushed the boundaries of its Nanadie Copper-Gold Project in WA, completing the deepest drillhole to date and logging visible copper sulphides well below previous resource levels. Assay results are pending, but early signs point to meaningful extensions of the mineralised system.

Alterity Therapeutics has secured FDA alignment on the chemistry and manufacturing controls for its ATH434 Phase 3 trial in Multiple System Atrophy, marking a pivotal regulatory milestone ahead of the planned mid-2026 End-of-Phase 2 meeting.

The FDA has removed the postmarketing cardiac repolarization study requirement for Clinuvel's SCENESSE®, reflecting confidence in its long-term safety profile. This marks a regulatory milestone for the only approved treatment for erythropoietic protoporphyria in the US.